Blood filter could shield vessels in septic shock

NCT ID NCT07711197

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial investigates whether a blood-filtering device called CytoSorb can reduce damage to blood vessels in people with septic shock, a life-threatening condition. The device removes inflammatory molecules from the blood. Researchers will measure changes in a marker of vessel injury and track organ function in 110 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CytoSorb hemoadsorption device used to filter blood and remove inflammatory molecules
What this could lead to
If successful, this approach could offer a new way to stabilize blood vessels and reduce organ failure in septic shock, potentially saving lives.
What could go wrong
This is a relatively small, early-stage trial, and the treatment may not improve outcomes or could cause complications like bleeding or clotting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sepsis toxic shock syndrome Vasoplegia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Semmelweis University, Department of Anaesthesiology and Intensive Therapy (Intenzív Terápiás Klinika).

    Budapest, 1082, Hungary

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.